| Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent. | |
| | |
MedLine Citation:
|
PMID: 18424375 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pemphigus vulgaris is a rare autoimmune blistering disease. Estimation of the incidence in Iran is one patient per 100,000 of the population per year. Mycophenolate mofetil is an immunosuppressive drug and successful treatment of pemphigus vulgaris and bullous pemphigoid has been reported with it, in combination with high dose prednisone, or as monotherapy. The present study describes our experience of the adjuvant use of mycophenolate mofetil in the management of 31 patients with pemphigus vulgaris as an initial treatment. We evaluated the efficacy and safety of mycophenolate mofetil combined with prednisolone in this cohort. We also assessed the relationship between the demographic indices/disease severity factors, and the failure of this treatment. In this study, mycophenolate mofetil was of definite benefit in 21 cases (67.7%). Generalized forms; patients with higher sum of the clinical scores at presentation; severe involvement of the groin; chest; face and limbs and those who had nail dystrophy also appeared to have poorer responses. When we excluded patients with generalized forms, only four patients were included in the failure group and the response rate reached 83.3%. It can be concluded that, except for generalized diseases, mycophenolate mofetil can be used safely and effectively in patients with pemphigus vulgaris as a first line, steroid sparing agent. |
| | |
Authors:
|
Nafiseh Esmaili; Cheyda Chams-Davatchi; Mahin Valikhani; Farshad Farshidfar; Nima Parvaneh; Banafshe Tamizifar |
Related Documents
:
|
21620625 - Serum metalloproteinases mmp-2, mmp-9, and metalloproteinase tissue inhibitors in patie... 21898075 - Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to syn... 22684485 - Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients? 14732665 - Treatment of refractory pemphigus vulgaris with rituximab (anti-cd20 monoclonal antibody). 8162135 - Speech and swallowing symptoms associated with parkinson's disease and multiple scleros... 10793435 - 24-hour heart rate variability in patients with vasovagal syncope. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: European journal of dermatology : EJD Volume: 18 ISSN: 1167-1122 ISO Abbreviation: Eur J Dermatol Publication Date: 2008 Mar-Apr |
Date Detail:
|
Created Date: 2008-04-21 Completed Date: 2008-07-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9206420 Medline TA: Eur J Dermatol Country: France |
Other Details:
|
Languages: eng Pagination: 159-64 Citation Subset: IM |
Affiliation:
|
Department of Dermatology, School of Medicine, Medical Sciences - University of Tehran, Tehran, Iran. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
administration & dosage,
therapeutic use* Adolescent Adult Anti-Inflammatory Agents / administration & dosage, therapeutic use Dermatologic Agents / administration & dosage, therapeutic use* Drug Therapy, Combination Female Follow-Up Studies Humans Immunosuppressive Agents / administration & dosage, therapeutic use* Male Middle Aged Mycophenolic Acid / administration & dosage, analogs & derivatives*, therapeutic use Pemphigus / drug therapy*, pathology Prednisolone / administration & dosage, therapeutic use Severity of Illness Index Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Anti-Inflammatory Agents; 0/Dermatologic Agents; 0/Immunosuppressive Agents; 128794-94-5/mycophenolate mofetil; 24280-93-1/Mycophenolic Acid; 50-24-8/Prednisolone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplas...
Next Document: Increased frequency of self-reported parasomnias in patients suffering from vitiligo.